<DOC>
	<DOCNO>NCT00805766</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety pharmacokinetics administration 10mg/kg TA-650 every 8 week patient Crohn 's disease show insufficient response previous treatment 5 mg/kg REMICADE every 8 week .</brief_summary>
	<brief_title>Efficacy Safety Increased Dose TA-650 ( Infliximab ) Patients With Crohn 's Disease ( CD )</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients Crohn 's disease Patients relapse symptom associate Crohn 's disease within 8 week spite maintenance treatment 5mg/kg REMICADE every 8 week , judge show insufficient response previous treatment physician Severe intestinal stricture ( may effect number loose stool diarrhea dilation colon small bowel proximal stricture barium radiograph inability traverse stricture endoscopy ) , diagnosis short bowel syndrome , previous stoma surgery The presence significant internal fistula ( possibility surgery might need , etc . ) confirm A history serious infusion reaction REMICADE Pregnant , lactating , probably pregnant woman Patients participated trial administer investigational product within 12 week consent Patients judge inadequate participate study physician</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>REMICADE</keyword>
	<keyword>Crohn 's disease</keyword>
</DOC>